The publication in a prestigious journal like Nature Reviews Neurology can enhance the credibility and visibility of Tiziana's lead candidate, intranasal foralumab. This could lead to increased investor interest and a positive impact on the stock price, as the market often reacts favorably to promising developments in biotech treatments.